Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/ HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial a randomized phase 3 clinical trial

1. Gianni, L.
2. Mansutti, M.
3. Anton, A.
4. Calvo, L.
5. Bisagni, G.
6. Bermejo, B.
7. Semiglazov, V.
8. Thill, M.
9. Chacon, J.I.
10. Chan, A.
11. Morales, S.
12. Alvarez, I.
13. Plazaola, A.
14. Zambetti, M.
15. Redfern, A.D.
16. Dittrich, C.
17. Dent, R.A.
18. Magazzu, D.
19. De Fato, R.
20. Valagussa, P.
21. Tusquets, I.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1001/JAMAONCOL.2017.4612 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus